Today, $CSPC PHARMA (01093.HK)$ Up over 5%, and as of press time, it rose by 5.09% to HKD 8.67, with a turnover of HKD 780 million.
In terms of developments, the latest data from the Hong Kong Stock Exchange shows that on December 22, Chairman and Executive Director Cai Dongchen increased his holding in CSPC Pharma by 13.454 million shares at an average price of HKD 8.1957 per share, for a total amount of approximately HKD 110 million. After the increase, his total shareholding amounts to approximately 2.91 billion shares, representing 25.26% of the company’s equity.
Recently, CSPC Pharma announced that the group’s developed drug, SYH2085 tablets, has received approval from the National Medical Products Administration (NMPA) of the People’s Republic of China to conduct clinical trials in China. The product is a self-developed Class 1 innovative chemical drug by the group, representing a novel oral small-molecule candidate drug capable of inhibiting the RNA polymerase acidic protein (PA) endonuclease activity of the influenza virus. The approved clinical indication is for the treatment of uncomplicated influenza A and B in adults and adolescents aged 12 years and above.
This product is expected to become an effective treatment for influenza, with high clinical development value, and will further enrich the group’s product pipeline in the field of anti-infective therapy.
Editor/KOKO